Floatz logo

Vocimagene Amiretrorepvec

IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)

Tocagen Inc.gene_therapyPhase 1Dormant
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
21/ 100
Competitive Position
95/ 100

Competitive context

109 Active assets in the IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting) cohort.

Asset / SponsorPhaseRating
Irinotecan
Kailin Yang, MD, PhD
Phase 2BB
Marizomib
Aadi Bioscience, Inc.
Phase 2BB
Valaciclovir
Trogenix ltd
Phase 2BB
Valproic Acid
Virginia Commonwealth University
Phase 2BB
DISODIUM 4-((TERT-BUTYLIMINO)METHYL)BENZENE-1,3-DISULFONATE N-OXIDE
Oblato, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

Vocimagene Amiretrorepvec is also rated in:

glioblastomaDormant
CCC
Indicative ·
48 / 100
View asset →
anaplastic astrocytomaDormant
CCC
Indicative ·
48 / 100
View asset →
anaplastic oligodendrogliomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →